Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -13.40% | 11.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.40% | 11.09% | |||
| Cost of Revenue | 10.63% | 11.76% | |||
| Gross Profit | -25.07% | 10.76% | |||
| SG&A Expenses | 54.14% | -27.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 34.10% | -13.14% | |||
| Operating Income | -129.32% | 247.91% | |||
| Income Before Tax | 96.48% | -37.32% | |||
| Income Tax Expenses | -59.63% | 1,286.81% | |||
| Earnings from Continuing Operations | 91.47% | -61.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 63.43% | -66.94% | |||
| Net Income | 88.83% | -62.37% | |||
| EBIT | -129.32% | 247.91% | |||
| EBITDA | -123.65% | 217.36% | |||
| EPS Basic | 88.89% | -63.64% | |||
| Normalized Basic EPS | 76.47% | -47.83% | |||
| EPS Diluted | 88.89% | -63.64% | |||
| Normalized Diluted EPS | 76.47% | -47.83% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||